MedBioSphere
Articles Videos The Web  
    

Bristol Myers Squibb and Gilead

Selected Abstract

Bristol-Myers Squibb and Gilead Sciences Establish U.S. Joint Venture to Develop and Commercialize Fixed-Dose Combination of Three HIV Medicines.
First Collaboration to Develop a Once-Daily Antiretroviral Fixed-Dose Regimen Bristol-Myers Squibb Company and Gilead Sciences, Inc. today announced details of a joint venture to develop and commercialize the fixed-dose combination of Bristol-Myers Squibb's Sustiva(R) (efavirenz) and Gilead's ...
December 20, 2004; PR Newswire

Read the full article with a free-trial membership at HighBeam Research



Related Articles

1. ].
2. Amgen to Acquire Avidia, a Privately Held Biopharmaceutical Company and Bristol-Myers Squibb and Gilead Sciences Establish Agreement to Commercialize ATRIPLA(TM).
3. Bristol-Myers Squibb and Gilead Sciences Submit New Drug Application to U.S. FDA for a Once-Daily Single Tablet Regimen of Sustiva(R) (Efavirenz) and Truvada(R) (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Treatment.
4. Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe.
5. Bristol-Myers Squibb and Gilead Sciences Establish Agreement to Commercialize ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) in Canada.
6. Bristol-Myers Squibb and Gilead Sciences Establish U.S. Joint Venture to Develop and Commercialize Fixed-Dose Combination of Three HIV Medicines.
7. Bristol-Myers Squibb and Gilead Announce Data Supporting Bioequivalence for Single-Pill Fixed-Dose Regimen of Sustiva(R) (efavirenz) and Truvada(R) (emtricitabine and tenofovir disoproxil fumarate).
8. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection.
9. European Commission Approves ATRIPLA(R) (Efavirenz 600 mg/Emtricitabine 200 mg/Tenofovir Disoproxil (as Fumarate) 245 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection.
10. One regimen, one pill, once a day.(New treatment combination)(Sustiva)(Truvada)(Emtriva)(Viread)(Brief Article)